U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to ...
Lexeo Therapeutics reports progress in US FDA discussions for accelerated approval pathway for LX2006 in Friedreich ataxia cardiomyopathy: New York Saturday, October 11, 2025, 16: ...
How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of ...
Pharmaceutical companies should look afresh at the business case for investing in ‘candidate’ biosimilars amidst signs that ...
Application Receives FDA Authorization to Proceed RALEIGH, NORTH CAROLINA / ACCESS Newswire / October 8, 2025 / Belhaven ...
The Type C meeting represents a formal opportunity for Merakris to engage with the FDA under its active Investigational New Drug (IND) application for the treatment of venous leg ulcers. The meeting ...
Stocktwits on MSN
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process
Lexeo Therapeutics (LXEO) announced on Tuesday that the company is considering a smaller pivotal study for LX2006 in the ...
TipRanks on MSN
Lexeo Therapeutics reports on LX2006 approval pathway
Lexeo Therapeutics (LXEO) announced updates to key components of an Accelerated Approval pathway for LX2006 in Friedreich ataxia, or FA, ...
Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.
How to build flexibility into your CGT manufacturing process while maintaining regulatory compliance
MasterControl research shows 40% of advanced therapy executives aren't confident they can meet CGT demand over the next three ...
ABS-CBN on MSN
Is the birth control pill destroying women's sex drive?
Decreased libido isn't listed on most birth control pill information leaflets. Yet, research shows it can affect libido — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback